Skip to main content
Equibles
DNLI logo

DNLI · Denali Therapeutics Inc. · Metrics

Track DNLI — free

Use DNLI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$22.08 -0.20 (-0.90%) At close · Sep 8
Russell 2000 member Rebalance outlook locked
Market Cap
$3.56B
Shares
159.85M

DNLI metrics

55 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$22.08
Market cap
$3.56B

Price action

20 metrics
Price change (1W)
-7.2%
Price change (30D)
-10.9%
Price change (3M)
+14.1%
Price change (6M)
+13.2%
Price change (YTD)
+34.9%
Price change (1Y)
+50.6%
Trailing year
Price change (5Y)
-59.1%
52-week high
$27.21
52-week low
$12.75
Change from 52-week high
-18.1%
Change from 52-week low
+74.7%
Annualized volatility
56.6%
Annualized volatility (3M)
49.4%
Beta
1.5
RSI (14D)
35.4
Price vs SMA 50
-8.8%
Price vs SMA 200
+6.9%
Avg volume (3M)
1.65M
Relative volume
0.5
Average dollar volume
$39.26M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
159.85M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
988.2×
reciprocal yield 0.1%
P / book
4.3
reciprocal yield 23.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-14.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$542.70M
Net income (TTM)
−$511.45M
Trailing 12 months
Diluted EPS (TTM)
$-2.84
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.32

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.60M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+9.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-61.2%
Return on assets
-44.2%
Debt / equity
—
Current ratio
8.4
EBITDA (TTM)
−$530.47M
Free cash flow (TTM)
—
Quick ratio
8.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$710.47M
Latest balance sheet
Cash & equivalents
$201.53M
Total assets
$1.16B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$434.04M
Capital expenditures (TTM)
$3.42M
R&D (TTM)
$400.72M
SG&A (TTM)
—
Stock compensation (TTM)
$95.09M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
297
13F filer change QoQ
+25
Institutional ownership
98.5%

Short interest

3 metrics
Short interest
11.2%
Latest settlement · 12.4 days to cover
Days to cover
12.4d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$398,435
Insider-sentiment score
56 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1714899 CUSIP 24823R105 13F (30d) 184 filings 184 filers Visit website Investor relations